test

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Conditions

Advanced Malignancies

What is the purpose of this trial?

The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Celldex Therapeutics
Dates:
September 2009
Last Updated:
October 24, 2013
Study HIC#:
0906005239

Clinicaltrials.gov ID: NCT00948961